Therapeutically, a recently described antibody recognizing a peptide encompassing the most common mutation of p53 in association with HLA-A02 has been transformed into a bispecific antibody that has been tested in preclinical in vivo models for its ability to retarget effector cells to tumor cells carrying the mutation (126). This evidence concerns the gene TP53 and neoplasm.